Oppenheimer analysts provided their views on Cross Country Healthcare, Inc. (NASDAQ:CCRN) following their meeting with the company’s executive management, noting that the company is positioned well for long-term success.

According to the analysts, the company looked to size the post-COVID market, highlighted its operational progress, and appeared open to disciplined capital deployment, which may include debt paydown and share repurchases.

The analysts expect solid Q2 results, estimating adjusted EPS/EBITDA of $1.35/$81 million, compared to the guidance of $1.30–1.40/$78–83 million.

Looking toward Q3 guidance, the analysts expect adjusted EPS/ EBITDA to decline to $1.02/$63.5 million (vs. Street’s $0.91/$58 million) as management has foreshadowed a steep decline in bill rates starting in Q3.